The Modern Management of Brain Metastases-AM2018
This session is a case-based education session with an expert panel encouraging audience participation. The session will center around the following topics, each centered around a clinical case that highlights important aspects of the topic supplemented by discussion from the panel and audience along with an overview of the relevant literature.
- Indications for WBRT vs. SRS.
- Indications for single fraction vs. fractionated SRS.
- Combining SRS/WBRT with immunotherapy/targeted therapy.
- Reirradiation of brain metastases; Management of local failures.
This activity is available from January 3, 2019 through 11:59 p.m. Eastern time on January 2, 2021.
This activity was originally recorded at ASTRO’s 2018 Annual Meeting, October 22-24, 2018 in San Antonio, TX.
This session is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, radiation oncology residents, radiation physicists, nurses, radiation therapists, and radiation dosimetrists.
- Explain the indications for radiosurgery vs. whole brain radiation in patients with multiple metastases.
- Determine the appropriate use for single fraction and hypofractionated treatment for brain metastases as well as how to approach patients with recurrent brain metastases.
- Describe the latest approaches to integrating new systemic therapy and immunotherapy into the radiotherapeutic management of brain metastases.
Eric Chang, MD is employed by the Keck School of Medicine, recieves compensation/remuneration/funding from AbbVie and BrainLab, and holds leadership positions at ARS and ASCO.
John Fiveash, MD is employed at the University of Alabama at Birmingham Department of Radiation Oncology and recieves compensation/remuneration/funding from Varian.
Jonathan Knisely, MD is employed at Weill Cornell Medicine and holds a leadership position at ASTRO.
Yoshiya Yamada, MD is employed at the Tohoku University Graduate School of Medicine and has nothing to disclose.
Additionally, the SA-CME Task Force and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.